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doi:10.1016/j.ejvs.2008.05.007Abstract Background: To study the long-term patency of thrombosed prosthetic vascular ac-
cess grafts treated with percutaneous mechanical thrombectomy (PMT) followed by aggressive
surveillance and monitoring and repeated endovascular interventions.
Study design: Two hundred seven vascular access grafts presented with first-time thrombosis
were treated with PMT using the AngioJet device (nZ 185) or the Arrow-Trerotola percutane-
ous thrombolytic device (nZ 22) followed by angioplasty ( stenting) of the anatomical lesion
responsible for the thrombotic event. Clinical success was considered at least one successful
subsequent hemodialysis session. Graft surveillance/monitoring included clinical and hemodi-
alysis parameters to detect a failing or thrombosed graft.
Results: PMT was technically successful in 202 cases (97.6%) and clinically successful in 193
cases (93.2%). During follow-up, 149 got thrombosed and either abandoned (nZ 33) or
underwent at least once repeat thrombectomy (nZ 116); finally 100 grafts were abandoned
(nZ 90), ligated (nZ 5) or removed (nZ 5). Endovascular management (0.54 procedures
per 100 graft-days, thrombectomy, nZ 307 sessions and angioplasty, nZ 162 sessions)
increased significantly functional assisted-primary patency rates from 29% and 14% at
1 and 2 years to a secondary patency of 62% and 47%, respectively. Secondary patency was
worse in loop grafts (PZ .02) and intermediate graft thrombosis (occurred between
31e182 days after graft placement, P<.001) and better when renal failure was due to
hypertension or diabetes (compared to other or cryptogenic causes, PZ .048) or isolated
angioplasty for graft dysfunction during follow-up had been performed (P<.001). Multivari-
ate analysis identified intermediate graft thrombosis and isolated angioplasty as indepen-
dent predictors of secondary patency (P<.001, relative risk 2.77 and P<.001, relative risk
0.28, respectively).d, MD, FACS, RVT, Vascular Surgery K-8, Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit,
; fax: þ1 313 9163023.
g (G.K. Haddad).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Age, years
Gender
Male
Female
Graft configurationc
Straight
Loop
Time from graft placement (mont
History of intervention for graft d
Time from last intervention (days
a Co-existing hypertension in 42 ca
b Included glomerulonephritis, pol
c Some patients had more than on
d Exact date of surgery not known i
or median and interquartile range; cConclusions: PMT is a highly successful procedure with acceptable long-term secondary
patency results, provided that aggressive endovascular management of subsequent throm-
botic or dysfunction episode is performed. Further research to identify the causes of inter-
mediate graft thrombosis is justified.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
The 2006 update of the KDOQI guidelines have recommen-
ded that endovascular techniques to restore function of
thrombosed hemodialysis prosthetic grafts, should have
a clinical success rate of at least 85% and that primary
patency at three months should be at least 40%.1 Variable
success and primary patency rates have been reported in
the literature.2e7. However, there is paucity of data on
the secondary patency of thrombosed prosthetic grafts
that were successfully restored7e9; endovascular interven-
tions can be performed on an outpatient basis and
repeated several times. We have previously published on
the assisted primary patency of thrombosed prosthetic
grafts and autogenous fistulae managed with percutaneous
mechanical thrombectomy (PMT).10 The aim of this study
was first to investigate the results of an aggressive protocol
of surveillance, monitoring and repeated endovascular in-
terventions on secondary patency rates of thrombosed
prosthetic vascular access grafts that presented with first-
time thrombosis and treated with PMT and second to iden-
tify prognostic factors associated with better outcome.
Material and Methods
During a 5-year period, 214 vascular access grafts (thigh
grafts, nZ 4 and upper arm grafts, nZ 210) presented with
first-time thrombosis. Two hundred and seven of them in 185
patients (85 men, mean age at presentation 61.9 years) were
treated with PMT, while in the remaining 7 grafts in sixpatients in relation to the caus
Cause of chronic re
Diabetes Mellitusa
(nZ 53)
64 10.9
29 (55%)
24 (45%)
38 (62%)
23 (38%)
hs)d 5.6 (1.9e16.2)
ysfunction 6 (12%)
, median) 183
ses.
ycystic kidney disease, nephrotic
e graft included in the study.
n 5 grafts placed at outside institu
ategorical data are given as numadditional patients, thrombectomy was aborted because
the access had an occlusive lesion that could not be crossed
with the hydrophilic wire (venous anastomosis, nZ 2, drain-
ing veins, nZ 3) or was deemed beyond endovascular
management (nZ 1) or this was attempted and aborted
(nZ 1). The hospital IRB approved the study. Patients that
had the first episode of graft thrombosis treated at outside
institutions were excluded from the study. The procedure
was deferred in medically unstable patients, e.g. intubated
etc, until patients recovered from the acute event. Time in-
terval between thrombotic episode and patient presentation
was not a contraindication to perform the procedure, if this
was less than a month. Two thrombectomy procedures per-
formed within the last month of a recurrent thrombosis was
also a contraindication for a new attempt and these grafts
were usually abandoned. Patient demographics are shown
in Table 1. Interval between graft placement to the first
thrombotic episode ranged from 13 days to 7.6 years. During
the period between graft placement and first thrombosis, 45
grafts had 86 preemptive interventions (range 1e5). Median
(interquartile range) time interval between the last preemp-
tive and the index PMT procedure was 117 (52e262) days.
Device Description
PMT was performed with the AngioJet device (Possis
Medical Inc., Minneapolis, Minn., USA, nZ 185) or the
Arrow-Trerotola percutaneous thrombolytic device (Arrow
International, Inc., Reading, Pa., USA, nZ 22). Device
selection was the operator’s choice.e of renal failure
nal failure
Hypertension
(nZ 102)
Otherb (nZ 23) Unknown (nZ 7) P value
63 14.5 56 11.9 48 21.5 .002
.94
56 (55%) 11 (48%) 4 (57%)
46 (45%) 12 (52%) 3 (43%)
.62
78 (68%) 14 (56%) 5 (71%)
36 (32%) 11 (44%) 2 (29%)
7.6 (2e17.5) 8.5 (2e18.3) 3.7 (2.4e34.6) .91
35 (33%) 3 (16%) 1 (14%) .02
106 122 53 .49
syndrome and other nephropathies.
tions. Continuous data are shown as mean and standard deviation
ber of cases (percentages).
Figure 1 This figure shows the device unit of the AngioJet
Ultra Thrombectomy System, which generates the high pres-
sure necessary to achieve isovolumetric balance between fluid
delivery and removal (courtesy of Possis Medical, Inc, Minneapo-
lis, MN, USA).
Figure 2 A radiograph of a thrombosed upper arm prosthetic
graft that underwent percutaneous mechanical thrombectomy
with the AngioJet device. Subsequent angiogram revealed the
presence of significant stenosis of the venous anastomosis
(arrow) and the body of the graft (arrowhead).
358 S.K. Kakkos et al.The AngioJet thrombectomy system (series 3000 and
Ultra, more recently, Fig. 1) uses a rheolytic thrombectomy
method. A detailed description can be found elsewhere.10
The Arrow-Trerotola percutaneous thrombolytic device
uses a rotating basket that fragments the thrombus that
is then removed from the sheath ports or flushed away by
the blood flow. Details can be found elsewhere.3
Description of Percutaneous Thrombectomy
Technique
A detailed description of the technique can be found
elsewhere.10e12 Briefly, our technique is a modification of
Beathard’s ‘‘double sheath technique’’2; Arterial throm-
bectomy is usually performed first instead and compro-
mised by the following steps:
1. Venous and arterial access. 2. Arterial thrombec-
tomy: This is performed under fluoroscopy with an over-
the-wire 4 Fr Fogarty thru-lumen embolectomy catheterFigures 3 (a,b) The presence and severity of the lesions
shown in Fig. 2 was confirmed during percutaneous balloon
angioplasty, as shown by the balloon waist (3a: venous anasto-
mosis, 3b: graft body) before they were fully dilated.
Table 2 Distribution of stenoses treated with angioplasty stenting during the initial thrombotic event in relation to graft
type
Location Graft typea P value Odds ratio (95% CI)
PTFE (nZ 105) Vecta (nZ 90) All grafts (nZ 205)b
Arterial anastomosis 44 (42%) 27 (30%) 76 (37%) .09 1.68 (0.93e3.05)
Graft 70 (67%) 51 (57%) 128 (62%) .15 1.53 (0.85e2.74)
Venous anastomosis 100 (95%) 87 (97%) 197 (96%) .73 0.69 (0.16e2.97)
Draining veins 61 (58%) 58 (64%) 127 (62%) .37 0.76 (0.43e1.37)
Central veins 27 (26%) 24 (27%) 55 (27%) .88 0.95 (0.50e1.81)
Number of stenosesc 3 (2e4) 3 (2e4) 3 (2e4) .39 N/A
Stent placement 5 (5%) 2 (2%) 8 (4%) .46 2.2 (0.42e11.6)
Graft age (months)c 7 (2.2e18.4) 5.4 (1.6e16.3) 6.6 (2e17) .14 N/A
a Not known in 12 grafts placed at outside institutions.
b Procedure abandoned in 2 additional grafts.
c median and interquartile range.
Secondary Patency of Thrombosed AV Grafts 359(Edwards Lifesciences, Irvine, CA) or a 6 mm balloon angio-
plasty catheter more recently, inflated with 50% contrast
solution.
3. Mechanical thrombectomy of the venous side: This
is performed with an AVX or DVX AngioJet catheter (Pos-
sis Medical, Inc) or Arrow-Trerotola percutaneous thrombo-
lytic device (Arrow International, Inc.) under fluoroscopic
guidance. 4. Angioplasty (arterial and/or venous) of
hemodynamically significant (50%) stenoses (Figs 2-4).
5. Hemostasis.
Definition of Outcomes
Technical success was considered a patent graft at the
conclusion of the procedure, based on a good thrill or fully
patent on angiogram. Clinical success was considered at
least one successful subsequent hemodialysis session.1
Reporting Standards for Arterio-Venous Accesses of the
Society for Vascular Surgery and the American Association
for Vascular Surgery were used to define postintervention
functional primary, functional assisted primary and func-
tional secondary graft patency.13 All grafts were followed
up to the end of postintervention secondary patency (final
thrombotic event), graft removal (because of infection),Table 3 Distribution of stenoses treated with angioplasty ste
since graft placement
Locationb Time since graft placement (months)a
1 (nZ 20) 1e3 (nZ 30) 3e
Arterial anastomosis 5 (25%) 9 (30%) 14
Graft 6 (30%) 16 (53%) 24
Venous anastomosis 11(55%) 29 (97%) 44
Draining veins 14 (70%) 12 (40%) 30
Central veins 3 (15%) 3 (10%) 10
Number of stenosesc 2 (1e3) 2 (1.8e3) 3
a Exact date of surgery not known in 5 grafts placed at outside inst
b Two grafts not included in the analysis because the procedure was
c Median and interquartile range.graft ligation, graft abandonment because of kidney trans-
plantation or recovered renal function or patient death.
Graft surveillance and monitoring protocol
Details appear elsewhere.10e12 This included clinical
parameters (surveillance: graft pain during hemodialysis,
prolonged bleeding time after hemodialysis and abnormal
findings on physical examination) and hemodialysis param-
eters [monitoring: high venous pressures (>300 mmHg),
suboptimal blood flow (<400 ml/min) or recirculation on
hemodialysis].1
Statistics
All data were analyzed with SPSS 14.0 for Windows (SPSS
Inc., Chicago, Ill, USA). Graft patency rates were calculated
with the Kaplan-Meier method and compared with the Log-
rank test. Cox regression was used for multivariate analysis.
Normally distributed data were expressed as mean (sd)
and compared with t-test, otherwise they were expressed
as median and interquartile (25the75th percentile) range
and Mann-Whitney or Kruskal-Wallis test was used. Cate-
gorical data were analyzed with the chi-square or Fisher’snting during the initial thrombotic event in relation to time
P value
6 (nZ 46) 7e12 (nZ 35) 12 (nZ 69)
(30%) 13 (37%) 32 (46%) .26
(52%) 22 (63%) 55 (80%) <.001
(96%) 35 (100%) 66 (96%) <.001
(65%) 20 (57%) 47 (68%) .08
(22%) 8 (23%) 28 (41%) .009
(2e3) 3 (2e4) 3 (3e5) <.001
itutions.
abandoned. In three additional grafts no stenosis was identified.
Figure 4 Results of balloon angioplasty of the lesions shown
in Figs. 2 and 3. The lesion at the venous anastomosis had a
residual stenosis and underwent repeat angioplasty with fur-
ther improvement, as shown in the right side of the image.
Table 4 Long-term postintervention functional patency
results. Endovascular management increased both primary
and postintervention assisted primary patency to a postin-
tervention secondary patency of 47% at 2 years
Postintervention functional
patency
Time (months)
3 6 12 24 P value
Primary 46% 32% 17% 6% e
Assisted primary 54% 44% 29% 14% .003
Secondary 77% 71% 62% 47% <.001
360 S.K. Kakkos et al.exact test where appropriate. A P value .05 was consid-
ered as significant.
Results
All 7 aborted cases had Vectra (C. R. Bard, Inc., Murray Hill,
N.J., USA) loop grafts and these were the only graft
characteristics that were different between aborted and
non-aborted cases (PZ .005 and PZ .001, respectively).
Using a per-protocol approach, PMT was technically suc-
cessful in 202 cases (97.6%, including 3 crossovers from
the Arrow-Trerotola to the AngioJet device and vice versa)
and clinically successful in 193 cases (93.2%); on an inten-
tion-to-treat approach these rates were 94.4% and 90.2%,
respectively.
Six patients (3.2%) developed adverse events,
including arterial embolism (successfully managedFigure 5 Kaplan-Meier curves of postintervention functional prim
grafts. Error bars on the survival curves represent the standard erro
the graph.percutaneously), allergic reaction, vomiting (that necessi-
tated the procedure to be aborted), a minor arm hema-
toma, resolved with conservative management, device tip
entrapment into a vein side branch (necessitating surgery)
and shortness of breath (requiring admission and work-up
that excluded pulmonary embolism). Thirty-day mortality
was 0%. Clinical success in grafts that presented with early
thrombosis (1 month since original surgery) was 75%,
compared to 96% in the remainder (PZ .004, odds ratio
7.3, 95% CI 2.1-24.9). There was also a trend for better clin-
ical success rates in PTFE grafts (96%) compared to Vectra
grafts (90%, PZ .085). There was no association between
clinical success and the remaining clinical parameters or
the location and total number of the responsible stenotic
lesions (arterial anastomosis, nZ 76, graft, nZ 128, ve-
nous anastomosis, nZ 197, draining veins, nZ 127 and
central veins, nZ 55). In 3 patients (1.4%) no stenosis was
identified. There was a trend toward arterial anastomosis
stenosis being more frequent in PTFE grafts (Table 2). A re-
lationship between graft age and the total number and also
the incidence of stenotic lesions at various locations was
also seen, as shown in Table 3. Four of the patients in which
PMT was not technically and/or clinically successful, were
managed with surgical thrombectomy (nZ 3) or repeat
PMT (nZ 1). Two of these grafts are still in use 2 ½ years
later.
Two patients were lost to follow-up, which left 195
grafts in the study. During follow-up, 39 of them remainedary, assisted primary and secondary patency of all thrombosed
r; the number of patients at risk at each interval is shown below
Table 5 Independent predictors of postintervention functional assisted primary patency
B SE Wald statistic P value Exp(B) (relative risk) 95% CI for Exp(B)
Age 0.015 0.006 6.222 .013 0.985 0.973e0.997
Diabetes 0.38 0.181 4.432 .035 0.68 0.48e0.97
Graft thrombosis within 3
months of placement
0.85 0.17 23.76 <.001 2.23 1.66e3.28
Re-intervention 0.58 0.17 11.63 .001 0.56 0.40e0.78
Secondary Patency of Thrombosed AV Grafts 361patent (25 of them dysfunction-free at 296 212 days fol-
low-up), seven were either removed for infection (nZ 3)
or ligated (for steal syndrome, nZ 1, venous hypertension,
nZ 1, graft pseudoaneurysm, nZ 1, anastomotic pseudoa-
neurysm, nZ 1) and 149 re- thrombosed and either aban-
doned (nZ 33, one of them removed later for infection)
or underwent redo thrombectomy (nZ 116). Three of these
116 grafts were later removed (for infection, nZ 2) or li-
gated (for dysfunction during placement of a new pros-
thetic graft, nZ 1), 56 were still patent at last follow-up
and 57 were finally abandoned (one of them removed later
for infection). Six additional patent grafts were abandoned,
because patients recovered renal function, spontaneously
(nZ 1) or after kidney transplant (nZ 5). Lastly, 9 grafts
(including the three grafts that were rescued after a failed
PMT, as described above) had surgical reintervention (five
surgical thrombectomies with intraoperative balloon angio-
plasty of the venous anastomosis in two of them, three
anastomotic revisions with interposition grafting, nZ 2 or
patch angioplasty, nZ 1 and one patch plasty for pseudoa-
neurysm) at a median of 170 days (range 8e854 days) after
the first thrombectomy. The total number of repeat PMTs
that was performed for graft thrombosis was 307 (median
2, range 1e10). Seventy-nine grafts developed at least
once dysfunction (total number 162, median 1, range 1e
8) and preemptive endovascular management was attemp-
ted. The total number of endovascular procedures that was
performed for graft dysfunction or thrombosis was 469,
which accounted for 0.54 procedures per 100 graft-days.Figure 6 Kaplan-Meier curves of postintervention secondary pa
placement; intermediate graft thrombosis (occurred between 31e1
ondary patency. Error bars on the survival curves represent the sta
shown below the graph.Long-term postintervention patency results are shown in
Table 4 and Fig. 5. A moderate but statistically significant
improvement of postintervention functional primary to
functional assisted primary patency was seen. Endovascular
management increased substantially postintervention
functional assisted primary patency rates from 27% and
14% at 1 and 2 years to a secondary patency of 62% and
47%, respectively.
Postintervention functional primary patency was worse in
patients younger than 62 years compared to older patients
(12% vs 21% at 12 months, PZ .04) and those with graft
thrombosis within 12 months of graft placement compared
to the remainder (10% vs 29% at 12 months, P<.001). On
multivariate analysis, only graft side and patient age were
significant (PZ .048 and PZ .001, respectively). The re-
maining patient demographics and graft characteristics had
no effect on postintervention primary patency rates.
Postintervention functional assisted primary patency
was better in the presence of an arterial anastomotic
stenosis, compared to its absence (39% vs 24% at 12 months,
PZ .04) or if re-intervention for graft dysfunction during
follow-up had been performed, compared to those grafts
this was not necessary (35% vs 25% at 12 months,
PZ .002) and worse for grafts that thrombosis occurred
within the first three months of graft placement compared
to later (36% vs 12% at 12 months, P<.001). Age, diabetes,
graft thrombosis within the first three months and re-
intervention for graft dysfunction during follow-up were
independent predictors of postintervention functionaltency of all thrombosed grafts in relation to time since graft
82 days after graft placement) was associated with worse sec-
ndard error; the number of patients at risk at each interval is
Figure 7 Kaplan-Meier curves of postintervention secondary patency of all thrombosed grafts in relation to the need for re-
intervention (angioplasty for graft dysfunction) during follow-up. Error bars on the survival curves represent the standard error;
the number of patients at risk at each interval is shown below the graph.
362 S.K. Kakkos et al.assisted primary patency on multivariate analysis (Table 5).
The remaining patient demographics, graft characteristics,
preemptive angioplasty for graft dysfunction before the
first thrombotic episode and PMT device type we used
had no effect on postintervention assisted primary patency
rates.
Postintervention functional secondary patency rates
were worse in loop grafts compared to straight configura-
tion (54% vs 66%, at 12 months, PZ .02) and in those with
intermediate graft thrombosis (occurred during the 2nd
and up to the 6th month after graft placement) compared
to the remainder (41% vs 75%, at 12 months, P<.001,
Fig. 6) and better when renal failure was due to hyperten-
sion or diabetes (compared to other or cryptogenic causes,
63% vs 58%, at 12 months, PZ .048) or if re-intervention for
graft dysfunction during follow-up had been performed
compared to those grafts this was not necessary (84% vs
46%, at 12 months, P<.001, Fig. 7). Remaining patient
demographics and graft characteristics, preemptive angio-
plasty for graft dysfunction before the first thrombotic
episode and PMT device type had no effect on postinterven-
tion secondary patency rates. Multivariate analysis with
Cox regression identified intermediate graft thrombosis
and re-intervention as independent predictors of worse
(P<.001, relative risk 2.77) and better (P<.001, relative
risk 0.28) postintervention secondary patency (Table 6
and Fig. 8).Discussion
Our study showed that aggressive management of throm-
bosed hemodialysis prosthetic grafts with PMT results notTable 6 Independent predictors of postintervention functional
B SE Wald statisti
Intermediate
thrombosis
1.019 0.208 23.926
Re-intervention 1.268 0.236 28.88only in acceptable postintervention primary and assisted-
primary patency, but also in very good secondary patency,
through multiple re-interventions for dysfunction and
recurrent thrombosis.
In the present study, we confirmed the excellent
technical and clinical success rates of rheolytic thrombec-
tomy.10 Clinical success rates were significantly lower in pa-
tients who developed early/intermediate graft thrombosis.
Thrombophilia is known to be associated with an increased
risk of graft thrombosis.14e16 Low inflow from coexisting
proximal arterial stenosis,17,18 and/or hypotensive episodes
during hemodialysis might had also contributed. Our clini-
cal success results far exceeded the recommended 85% tar-
get, set by the KDOQI guidelines, which we attribute to the
aggressive use of angioplasty and early patient referral,
since technical and clinical success are both significantly
better in patients presenting for PMT less than 3 days after
the thrombotic episode.10
A significant association between the total number and
pattern of stenotic lesions diagnosed during the initial
thrombectomy and graft age was observed in the current
study. As grafts become older the total number of stenoses
associated with graft thrombosis increases; with the
exception of draining vein stenosis, this pattern was seen
in all locations, including central veins. Although the
increased incidence of stenoses in older grafts seems
expected, we were surprised to find that central vein
stenosis, traditionally attributed to previous catheter use,
followed the same pattern; it is well known that central
vein stenoses are not always the result of previous cathe-
ters19,20; increased blood flow through the access causing
turbulence and vibration can also stimulate intimal hyper-
plasia,21 which could explain our findings. The incidencesecondary patency
c P value Exp(B) (relative risk) 95% CI for Exp(B)
<.001 2.77 1.84e4.17
<.001 0.28 0.18e0.45
Figure 8 Kaplan-Meier curves of postintervention secondary patency of all thrombosed grafts in subgroups defined by time since
graft placement and the need for re-intervention (IN: intermediate, NI: non-intermediate). Subgroup comparisons were all statis-
tically significant with the exception of the IN-reintervention and NI-no reintervention groups comparison. Error bars on the survival
curves represent the standard error; the number of patients at risk at each interval is shown below the graph.
Secondary Patency of Thrombosed AV Grafts 363of midgraft stenosis,22 related to repeated graft puncture
for hemodialysis, showed, as expected, a linear association
with time, but on the other hand an increased incidence of
venous anastomosis stenosis was observed very early.
A variable incidence of complications of percutaneous
thrombectomy and thrombolysis of prosthetic grafts has
been reported, this being between 3%-16%.2,4,6,23,24 Serious
complications, like pulmonary embolism or death,6,23e27
were not observed in our series. The single episode of arte-
rial embolism we encountered was managed promptly with
rheolytic thrombectomy. Arterial emboli has been previ-
ously described to occur after open thrombectomy,28 and
probably in our case it was the result of the balloon throm-
bectomy of the arterial anastomosis and proximal graft.
Like others, we favor an aggressive endovascular
approach in treating failing or thrombosed accesses. Being
minimally invasive, they are easily accepted by the
patients. The high rate of clinical effectiveness and the
fact that the access can be used immediately are additional
factors that favor these methods. As shown in the current
report, as grafts become older they tend to develop
multiple and probably more virulent stenoses, resistant to
angioplasty or prone to recur and this puts a limit on the
number of attempts to treat recurrent graft thrombosis.
Valji reported that shorter intervals between graft throm-
boses is a predictor of earlier subsequent graft failure.7 We
have observed a similar pattern.
There has been considerable debate on the role of open
versus percutaneous graft thrombectomy, especially in the
past. Endovascular procedures do not burn the venous
capital, i.e. the draining vein distal to the venous anasto-
mosis is spared for future graft revision. This might be one
of the reasons better results have been reported with
revision surgery than percutaneous methods,29 however
percutaneous interventions performed by experienced
operators can yield equivalent results30; endovascular tech-
niques are also continuously evolving. A new anastomosis
with a healthy vein might last longer than a diseased one
that underwent angioplasty, however a recent large studythat compared surgical thrombectomy alone with adjuvant
angioplasty (on-table or sequential) and revision of the
venous anastomosis with either patch angioplasty or jump
graft, showed that the last three methods had the same
patency results but consistently better than the first
method.31 Surgery in our series had a very limited role in
managing grafts with failed endovascular interventions or
late complications.
Our postintervention primary patency results far
exceeded the recommended target of 40% three-month
primary unassisted patency set by the KDOQI guidelines,1
and what has been reported by most studies in the litera-
ture,2e4,6,7,29,32,33 which we attribute to the thorough use
of angiography to identify the responsible stenotic lesion(s)
and to angioplasty to treated those. We observed a steep
decline in postintervention primary patency curve during
the first few months, consistent with previous observa-
tions.7 The cause of early recurrent graft thrombosis is
obviously associated with recurrence of the original
stenotic lesions enhanced possibly by the presence of addi-
tional risk factors like hypercoagulopathy14; this serious
problem should be addressed by further research. Surveil-
lance and monitoring coupled with endovascular interven-
tions increased the postintervention primary patency by
an absolute value of 12% at 6 and 12 months to the assisted
primary patency rates shown in Table 4. Grafts in younger
patients and those with early/intermediate thrombosis
had worse primary and assisted primary patency, which
indicates that the process responsible for graft thrombosis
might had been more virulent, for example a higher inci-
dence of thrombophilia and more aggressive myointimal
hyperplasia. Compared to three previous studies (two of
them from the 1990’s) that reported on one-year postinter-
vention secondary patency rates of 53%,9 51%7 and around
10%,8 following percutaneous thrombectomy or thromboly-
sis, our results of postintervention secondary patency (62%
and 47% at one and two years, respectively) are signifi-
cantly better and were maintained at 3 years. We attribute
this to the aggressive use of balloon angioplasty during the
364 S.K. Kakkos et al.initial and subsequent thrombectomies and repeat endo-
vascular management of failing or thrombosed grafts; obvi-
ously the decision on when to abandon a graft is very
crucial in determining secondary patency and this can be
variable in different practices; we did not give up unless
the patient had two recent thrombectomies performed or
the patient was medically unstable. The KDOQI guidelines
have not proposed a particular target for postintervention
secondary patency of thrombosed prosthetic grafts, proba-
bly because of the lack of data to support such a recommen-
dation; based on the results of our contemporary protocol
we believe that targets for secondary patency at 3, 6 and
12 months should be set at least to 70%, 60% and 50%,
respectively.
Postintervention patency in this study was predicted by
several parameters, with the most striking being graft age
and re-intervention for graft failure; Valji and colleagues
reported that graft age did not influence future graft
patency, but they had a small number of grafts, especially
grafts placed less than one year before the thrombectomy.7
This worse patency could simply be reflective of the cause
that led to the initial graft thrombosis, irrespectively of its
nature, i.e. technical, hypercoagulopathy or development
of myointimal hyperplasia. The established role of graft
surveillance/monitoring and appropriate preemptive angio-
plasty was shown, as expected, in our study to be signifi-
cant, confirming previous studies.10,12,34 Future studies
could be focused on these high-risk groups. Finally, we
believe that better thrombectomy methods will not
improve long-term patency and that future research should
be focused in methods to prevent and treat more effec-
tively arterial and venous anastomosis, intragraft and
remote stenotes responsible for recurrent graft failure.
In conclusion, PMT of thrombosed prosthetic grafts is
a highly successful procedure with acceptable long-term
postintervention secondary patency, provided that an
aggressive policy of endovascular management is estab-
lished to manage subsequent episodes of thrombosis and/or
dysfunction. Further research to identify the causes of
intermediate graft thrombosis is justified.
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